Chemotherapy News and Research

Latest Chemotherapy News and Research

Results from Janssen's ZYTIGA plus prednisone Phase 3 study on mCRPC

Results observed from pre-specified interim analyses of the randomized, placebo-controlled Phase 3 study, COU-AA-302, demonstrated that patients with metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone acetate (ZYTIGA) plus prednisone showed a statistically significant improvement in radiographic progression-free survival (rPFS) and all secondary endpoints compared to patients treated with placebo plus prednisone.

4 Jun 2012

Genentech’s T-DM1 Phase III study on HER2-positive mBC meets primary endpoint

Genentech, a member of the Roche Group, today announced that the Phase III EMILIA study of trastuzumab emtansine (T-DM1) met its co-primary endpoint of a significant improvement in the time people with HER2-positive metastatic breast cancer (mBC) lived without their disease getting worse (progression-free survival, PFS).

4 Jun 2012

Roche to initiate three studies with T-DM1 for early stage HER2-positive breast cancer

ImmunoGen, Inc., a biotechnology company with a proprietary Targeted Antibody Payload (TAP) technology, today announced that Roche is implementing a "three-pronged approach" to developing trastuzumab emtansine (T-DM1) for early stage HER2-positive breast cancer, according to plans outlined by Roche at its 2012 ASCO analyst event.

4 Jun 2012

Favorable results from CytRx’s INNO-206 Phase 1b/2 trial on soft tissue sarcomas

CytRx Corporation, a biopharmaceutical company specializing in oncology, announces that favorable clinical results from its Phase 1b/2 clinical trial with its tumor-targeting doxorubicin conjugate INNO-206 in patients with advanced solid tumors, primarily soft tissue sarcomas, are being presented today at the American Society of Clinical Oncology (ASCO) conference in Chicago.

4 Jun 2012

Study reveals why GBM is highly resistant to current chemotherapies

New research from the University of Wisconsin-Madison explains why the incurable brain cancer, glioblastoma multiforme (GBM), is highly resistant to current chemotherapies.

2 Jun 2012

ZYTIGA Phase 3 study for metastatic prostate cancer presented at 48th ASCO

New data presented this weekend at the 48th annual meeting of the American Society of Clinical Oncology (ASCO) showed ZYTIGA (abiraterone acetate) may prove to be an important new treatment option for metastatic prostate cancer patients prior to receiving chemotherapy.

2 Jun 2012

Lapatinib-pazopanib combination therapy not beneficial for patients with inflammatory breast cancer

Inflammatory breast cancer is a very aggressive type of cancer associated with early metastasis and poor survival rates, and the prognosis is even worse for patients with tumors expressing the ErbB2 receptor. The ErbB2-inhibiting drug lapatinib can slow the spread of cancer cells in individuals with advanced breast cancer who have already tried other chemotherapy medications.

2 Jun 2012

Studies support diagnostic utility of molecular classification in difficult-to-diagnose metastatic cancer

bioTheranostics, Inc., developer of innovative oncology diagnostic tests and solution provider for metastatic cancer, today announced findings from two studies showing high diagnostic accuracy for CancerTYPE ID in determining the primary tumor site in high-grade, metastatic tumors. Results were reported at the 2012 annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago.

2 Jun 2012

'Atzelberg Circle' researchers meet to advance hyperthermia as standard combination cancer therapy

BSD Medical Corporation, a developer and manufacturer of advanced medical systems that utilize heat therapy to treat cancer, announced today that a distinguished, international team of leading oncologists met in council while attending the May 2012 conference of the European Society for Radiotherapy and Oncology (ESTRO) in Barcelona, Spain.

2 Jun 2012

New medication proves effective in slowing the spread of metastatic prostate cancer

A new medication proved effective in slowing the spread of metastatic prostate cancer, while helping to maintain the quality of life, in patients with advanced disease. The phase 3 study was unblinded midway, allowing patients receiving the placebo to instead take the drug because of the favorable results.

2 Jun 2012

Agendia launches ColoPrint microarray-based 18-gene expression signature for colon cancer

Agendia, an innovative molecular cancer diagnostics company and leader in personalized medicine, today announced the launch of its ColoPrint microarray-based 18-gene expression signature for predicting the risk of distant recurrence for stage II colon cancer patients who have undergone surgery.

2 Jun 2012

Precision Therapeutics’ ChemoFx test feasible in cervical cancer

Precision Therapeutics announces the acceptance of a new abstract on the ChemoFx® in vitro drug response marker for publication in conjunction with the American Society of Clinical Oncology (ASCO) 2012 Annual Meeting.

2 Jun 2012

HNC patients may be at increased risk for post-treatment side effects

New data from an Internet-based study show that patients with head and neck cancers (HNC) may be at risk for significant late effects after their treatment, but they're unlikely to discuss these and other survivorship care issues with their doctors.

2 Jun 2012

Liver metastases predicts shorter overall survival in men with mCRPC

Liver metastases predicts shorter overall survival in men with metastatic castration-refractory prostate cancer (mCRPC), according to data being presented at the 2012 American Society of Clinical Oncology Annual Meeting in Chicago.

2 Jun 2012

Inhibiting IRE1α-XBP1 pathway impacts survival of myeloma cells

Results published in Blood, the official journal of the American Society of Hematology, confirm that inhibition of the IRE1α-XBP1 pathway impacts the survival of myeloma cells, suggesting a promising therapeutic option in multiple myeloma.

2 Jun 2012

Montefiore experts available to discuss cancer research at 2012 ASCO meeting

Bringing together international experts with the latest technologies and pioneering research, Montefiore Einstein Center for Cancer Care, in collaboration with the National Cancer Institute-designated Albert Einstein Cancer Center, advances the front lines of prevention, diagnosis and treatment of rare and common cancers.

2 Jun 2012

Distinctive protein pathways in certain leukemia patients

Scientists at Rice University and the University of Texas MD Anderson Cancer Center have successfully profiled protein pathways found to be distinctive to leukemia patients with particular variants of the disease.

1 Jun 2012

Results from A.P. Pharma’s APF530 Phase 3 trial on CINV

A.P. Pharma, Inc., a specialty pharmaceutical company, today announced that an abstract analyzing a subset of efficacy results from its Phase 3 trial of APF530 has been published in conjunction with the American Society of Clinical Oncology's (ASCO) 2012 Annual Meeting.

1 Jun 2012

Viewpoints: Bishops' request for contraception exemption may push legal precedent; Maine's experiment on health care

43 Roman Catholic organizations have filed lawsuits challenging a ... regulation that requires employers or their health insurers to offer birth control coverage to workers. The plaintiffs say that complying with the regulation would violate their religious freedom.

1 Jun 2012

NCI, Tau Therapeutics open enrollment in mibefradil Phase Ib glioma trial

Tau Therapeutics LLC, a pharmaceutical company developing T-type calcium channel inhibitors for the treatment of solid tumors, announced today that it has opened enrollment for a Phase Ib clinical trial with the National Cancer Institute's Adult Brain Tumor Consortium (ABTC) using the company's first product candidate mibefradil.

1 Jun 2012

Chemotherapy News and Research

Latest Chemotherapy News and Research

Results from Janssen's ZYTIGA plus prednisone Phase 3 study on mCRPC

Genentech’s T-DM1 Phase III study on HER2-positive mBC meets primary endpoint

Roche to initiate three studies with T-DM1 for early stage HER2-positive breast cancer

Favorable results from CytRx’s INNO-206 Phase 1b/2 trial on soft tissue sarcomas

Study reveals why GBM is highly resistant to current chemotherapies

ZYTIGA Phase 3 study for metastatic prostate cancer presented at 48th ASCO

Lapatinib-pazopanib combination therapy not beneficial for patients with inflammatory breast cancer

Studies support diagnostic utility of molecular classification in difficult-to-diagnose metastatic cancer

'Atzelberg Circle' researchers meet to advance hyperthermia as standard combination cancer therapy

New medication proves effective in slowing the spread of metastatic prostate cancer

Agendia launches ColoPrint microarray-based 18-gene expression signature for colon cancer

Precision Therapeutics’ ChemoFx test feasible in cervical cancer

HNC patients may be at increased risk for post-treatment side effects

Liver metastases predicts shorter overall survival in men with mCRPC

Inhibiting IRE1α-XBP1 pathway impacts survival of myeloma cells

Montefiore experts available to discuss cancer research at 2012 ASCO meeting

Distinctive protein pathways in certain leukemia patients

Results from A.P. Pharma’s APF530 Phase 3 trial on CINV

Viewpoints: Bishops' request for contraception exemption may push legal precedent; Maine's experiment on health care

NCI, Tau Therapeutics open enrollment in mibefradil Phase Ib glioma trial

Cancer Research - Second Edition eBook

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Chemotherapy News and Research

Latest Chemotherapy News and Research

Cancer Research - Second Edition eBook

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Newsletters you may be interested in